ClinicalTrials.gg
CompletedNCT00853749REPLAYUpdated Nov 11, 2021Results posted

Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine

A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine (13vPnC) and Blood draw in Invasive Pneumococcal Disease, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 2 sites in Iceland. Open to participants aged 5 Years to 7 Years. Per ClinicalTrials.gov, last updated 2021-11-11.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
89
Allocation
Non-randomized
Ages
5 Years to 7 Years
Sex
All
01

Study summary

The primary purpose of this study is to evaluate the immune response to 13-valent pneumococcal conjugate vaccine (13vPnCV) in children who as infants received either a complete series of PnCV versus a combination of PnCV and pneumococcal polysaccharide vaccine (PSV). This study is also intended to evaluate the safety of the 13vPnC.

Read the detailed description

Follow-up measure for the EMEA supporting a Type II variation for Prevenar (PCV7) label

02

Conditions studied

  • Invasive Pneumococcal Disease

Keywords

  • Immune response
  • pneumococcal conjugate vaccine
  • polysaccharide
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fully vaccinated children who participated in a previous Wyeth study (Study D139-P506) and received a booster dose of either 23-valent pneumococcal polysaccharide vaccine (PPV23) or pneumococcal conjugate vaccine (PnCV) per the original protocol for that study.
  • Subjects must be in good health as determined by medical history, physical examination and clinical judgment.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to any component of the 7-valent pneumococcal conjugate vaccine (7vPnC) or 13-valent pneumococcal conjugate vaccine (13vPnC).
  • History of documented invasive pneumococcal disease (defined as a positive culture of S. pneumoniae from a normally sterile body site).
  • Any known or suspected disease or dysfunction of the immune system, including: infection, , Receipt of therapy, Sickle cell hemoglobinopathy.
  • Receipt of immune-globulin within the past 3 months.
  • Receipt of either PSV or 7vPnCV since the completion of Study D139-P506.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Non-randomized
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Other
    Single

    All subjects will receive a single dose of 13vPnC

    Biological: 13-valent pneumococcal conjugate vaccine (13vPnC) · Procedure: Blood draw

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per Milliliter (mcg/mL) Measured 1 Month After Vaccination

    Percentage of participants achieving predefined antibody threshold ≥ 0.35 mcg/mL along with the corresponding 95 percent (%) Confidence Interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

    Time frame: Day 28

  2. Percentage of Participants Achieving Opsonophagocytic Assay (OPA) Titers ≥ 1:8 Measured 1 Month After Vaccination

    Percentage of participants achieving OPA along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

    Time frame: Day 28

Secondary outcomes

  1. Antibody Response Measured 1 Month After Vaccination (Avidity Assay)

    Avidity assay had measurable range of 0.117 to 7.5. Results expressed as avidity index (AI). Geometric mean avidity presented for 3 common pneumococcal serotypes (serotype 6B, 19F, and 23F) and 2 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1 and 5).

    Time frame: Day 28

  2. Antibody Response Measured 1 Month After Vaccination (OPA)

    Antibody response as measured by OPA, 1 month after vaccination. Geometric mean titers (GMTs) calculated using all participants with available data for the specified blood draw. CIs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: Day 28

Other outcomes

  1. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal IgG Antibody 1 Month After Vaccination

    Antibody GMC as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. CIs were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. GMCs were calculated using all participants with available data for the specified blood draw.

    Time frame: Day 28

  2. Percentage of Participants Reporting Prespecified Local Reactions Within 4 Days of Vaccination

    Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may have been represented in more than 1 category.

    Time frame: Day 1 through Day 4

  3. Percentage of Participants Reporting Prespecified Systemic Reactions Within 4 Days of Vaccination

    Pre-specified systemic events (any fever 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using a diary card. Participants may have been represented in more than 1 category.

    Time frame: Day 1 through Day 4

07

Results

Posted Jan 5, 2011
Limitations and caveats
Primary analysis based on evaluable immunogenicity population as per analysis plan change.Data for a participant reported in PCV/23vPS/13vPnC instead of PCV/PCV/13vPnC due to data entry error on case report form;this did not affect result conclusion.

Participant flow

Participant flow — Overall Study
MilestonePCV/23vPS/13vPnCPCV/PCV/13vPnC
Started5039
Vaccinated5039
Completed5038
Not completed01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryPercentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per Milliliter (mcg/mL) Measured 1 Month After Vaccination

Percentage of participants achieving predefined antibody threshold ≥ 0.35 mcg/mL along with the corresponding 95 percent (%) Confidence Interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

Time frame:
Day 28
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per Milliliter (mcg/mL) Measured 1 Month After Vaccination
Percentage of participantsPCV/23vPS/13vPnCPCV/PCV/13vPnC
Common Serotype 4100.0 (92.9 to 100.0)97.3 (85.8 to 99.9)
Common Serotype 6B100.0 (92.9 to 100.0)100.0 (90.5 to 100.0)
Common Serotype 9V100.0 (92.9 to 100.0)100.0 (90.5 to 100.0)
Common Serotype 14100.0 (92.7 to 100.0)100.0 (90.5 to 100.0)
Common Serotype18C100.0 (92.9 to 100.0)97.3 (85.8 to 99.9)
Common Serotype 19F100.0 (92.9 to 100.0)100.0 (90.5 to 100.0)
Common Serotype 23F100.0 (92.9 to 100.0)100.0 (90.5 to 100.0)
Additional Serotype 1100.0 (92.9 to 100.0)97.3 (85.8 to 99.9)
Additional Serotype 3100.0 (92.9 to 100.0)100.0 (90.5 to 100.0)
Additional Serotype 5100.0 (92.9 to 100.0)100.0 (90.5 to 100.0)
Additional Serotype 6A100.0 (92.9 to 100.0)100.0 (90.5 to 100.0)
Additional Serotype 7F100.0 (92.9 to 100.0)100.0 (90.5 to 100.0)
Additional Serotype 19A100.0 (92.9 to 100.0)100.0 (90.5 to 100.0)
Statistical analysis
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 2.7 · 95% CI -5.0 to 14.2
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.3 to 9.5
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.3 to 9.5
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.8 to 9.5
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 2.7 · 95% CI -5.0 to 14.2
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.3 to 9.5
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.3 to 9.5
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 2.7 · 95% CI -5.0 to 14.2
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.3 to 9.5
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.3 to 9.5
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.3 to 9.5
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.3 to 9.5
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.3 to 9.5
PrimaryPercentage of Participants Achieving Opsonophagocytic Assay (OPA) Titers ≥ 1:8 Measured 1 Month After Vaccination

Percentage of participants achieving OPA along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

Time frame:
Day 28
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Opsonophagocytic Assay (OPA) Titers ≥ 1:8 Measured 1 Month After Vaccination
Percentage of participantsPCV/23vPS/13vPnCPCV/PCV/13vPnC
Common Serotype 498.0 (89.4 to 99.9)97.2 (85.5 to 99.9)
Common Serotype 6B100.0 (92.7 to 100.0)100.0 (90.3 to 100.0)
Common Serotype 9V100.0 (92.7 to 100.0)100.0 (90.3 to 100.0)
Common Serotype 14100.0 (92.7 to 100.0)100.0 (90.3 to 100.0)
Common Serotype 18C100.0 (92.9 to 100.0)100.0 (90.0 to 100.0)
Common Serotype 19F100.0 (92.7 to 100.0)100.0 (90.0 to 100.0)
Common Serotype 23F98.0 (89.4 to 99.9)100.0 (89.7 to 100.0)
Additional Serotype 1100.0 (92.9 to 100.0)97.3 (85.8 to 99.9)
Additional Serotype 398.0 (89.1 to 99.9)100.0 (90.3 to 100.0)
Additional Serotype 598.0 (89.4 to 99.9)97.3 (85.8 to 99.9)
Additional Serotype 6A100.0 (92.9 to 100.0)100.0 (90.5 to 100.0)
Additional Serotype 7F98.0 (89.4 to 99.9)100.0 (90.3 to 100.0)
Additional Serotype 19A100.0 (92.9 to 100.0)100.0 (90.5 to 100.0)
Statistical analysis
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.8 · 95% CI -8.6 to 12.7
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.5 to 9.7
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.5 to 9.7
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.5 to 9.7
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.4 to 10.0
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.5 to 10.0
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): -2.0 · 95% CI -10.8 to 8.1
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 2.7 · 95% CI -5.0 to 14.2
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): -2.0 · 95% CI -11.1 to 7.9
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.7 · 95% CI -8.5 to 12.2
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.3 to 9.5
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): -2.0 · 95% CI -11.3 to 7.7
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Difference in proportions (percentage): 0.0 · 95% CI -7.3 to 9.5
SecondaryAntibody Response Measured 1 Month After Vaccination (Avidity Assay)

Avidity assay had measurable range of 0.117 to 7.5. Results expressed as avidity index (AI). Geometric mean avidity presented for 3 common pneumococcal serotypes (serotype 6B, 19F, and 23F) and 2 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1 and 5).

Time frame:
Day 28
Reported as:
Geometric mean · AI
Antibody Response Measured 1 Month After Vaccination (Avidity Assay)
AIPCV/23vPS/13vPnCPCV/PCV/13vPnC
Additional serotype 11.42 (1.15 to 1.76)4.68 (3.62 to 6.04)
Additional serotype 51.85 (1.46 to 2.36)5.85 (4.81 to 7.11)
Common serotype 6B2.43 (1.77 to 3.35)5.48 (4.38 to 6.86)
Common serotype 19F2.17 (1.69 to 2.79)2.46 (1.88 to 3.21)
Common serotype 23F3.02 (2.36 to 3.85)6.43 (5.33 to 7.76)
Statistical analysis
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of geometric means: 0.30 · 95% CI 0.22 to 0.42CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of geometric means: 0.32 · 95% CI 0.23 to 0.44CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures ((PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of geometric means: 0.44 · 95% CI 0.29 to 0.67CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of geometric means: 0.88 · 95% CI 0.61 to 1.27CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of geometric means: 0.47 · 95% CI 0.34 to 0.65CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
SecondaryAntibody Response Measured 1 Month After Vaccination (OPA)

Antibody response as measured by OPA, 1 month after vaccination. Geometric mean titers (GMTs) calculated using all participants with available data for the specified blood draw. CIs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
Day 28
Reported as:
Geometric mean · GMT
Antibody Response Measured 1 Month After Vaccination (OPA)
GMTPCV/23vPS/13vPnCPCV/PCV/13vPnC
Common Serotype 42374 (1656.3 to 3404.0)3765 (2339.1 to 6059.8)
Common Serotype 6B11156 (9073.5 to 13715.2)11477 (8418.5 to 15646.8)
Common Serotype 9V1651 (1067.8 to 2553.3)1713 (1087.0 to 2700.0)
Common Serotype 143041 (2311.4 to 4001.1)3048 (2318.3 to 4006.9)
Common Serotype 18C3230 (2616.1 to 3987.1)5684 (3122.2 to 10349.6)
Common Serotype 19F1266 (1013.9 to 1582.0)1198 (842.3 to 1703.9)
Common Serotype 23F1678 (1212.3 to 2322.1)2714 (1970.1 to 3739.5)
Additional Serotype 1217 (162.6 to 290.5)1087 (717.5 to 1646.3)
Additional Serotype 3153 (117.2 to 200.2)188 (146.6 to 240.8)
Additional Serotype 5264 (178.5 to 389.9)719 (500.9 to 1032.4)
Additional Serotype 6A7060 (5352.2 to 9312.6)5034 (3336.6 to 7594.4)
Additional Serotype 7F5835 (4160.0 to 8184.1)7887 (6447.9 to 9647.0)
Additional Serotype 19A1256 (990.9 to 1591.9)1556 (1108.8 to 2182.2)
Statistical analysis
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmts: 0.6 · 95% CI 0.35 to 1.12CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmts: 1.0 · 95% CI 0.68 to 1.38CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmts: 1.0 · 95% CI 0.51 to 1.81CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmts: 1.0 · 95% CI 0.67 to 1.48CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmts: 0.6 · 95% CI 0.33 to 0.98CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures(PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmts: 1.1 · 95% CI 0.72 to 1.56CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmts: 0.6 · 95% CI 0.39 to 0.99CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmts: 0.2 · 95% CI 0.12 to 0.32CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmts: 0.8 · 95% CI 0.56 to 1.18CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmts: 0.4 · 95% CI 0.21 to 0.63CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmts: 1.4 · 95% CI 0.88 to 2.25CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmts: 0.7 · 95% CI 0.48 to 1.14CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmts: 0.8 · 95% CI 0.54 to 1.20CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
Other pre-specifiedGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal IgG Antibody 1 Month After Vaccination

Antibody GMC as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. CIs were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. GMCs were calculated using all participants with available data for the specified blood draw.

Time frame:
Day 28
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal IgG Antibody 1 Month After Vaccination
mcg/mLPCV/23vPS/13vPnCPCV/PCV/13vPnC
Common serotype 44.18 (3.38 to 5.16)11.34 (7.74 to 16.62)
Common serotype 6B29.51 (21.32 to 40.83)41.70 (29.01 to 59.96)
Common serotype 9V4.31 (3.68 to 5.04)7.39 (6.05 to 9.03)
Common serotype 1417.47 (12.76 to 23.93)22.78 (15.75 to 32.96)
Common serotype 18C2.76 (2.15 to 3.56)4.83 (3.48 to 6.71)
Common serotype 19F9.78 (7.45 to 12.83)11.60 (8.46 to 15.92)
Common serotype 23F7.89 (6.18 to 10.07)12.25 (8.92 to 16.81)
Additional serotype 15.28 (4.22 to 6.61)19.43 (13.77 to 27.41)
Additional serotype 33.28 (2.44 to 4.41)2.87 (2.19 to 3.76)
Additional serotype 55.75 (4.64 to 7.12)15.98 (11.99 to 21.30)
Additional serotype 6A11.16 (8.80 to 14.16)14.07 (10.64 to 18.61)
Additional serotype 7F7.13 (5.67 to 8.96)8.05 (5.94 to 10.91)
Additional serotype 19A14.62 (11.49 to 18.59)17.07 (12.92 to 22.55)
Statistical analysis
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmcs: 0.37 · 95% CI 0.25 to 0.55CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmcs: 0.71 · 95% CI 0.44 to 1.15CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmcs: 0.58 · 95% CI 0.45 to 0.75CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmcs: 0.77 · 95% CI 0.48 to 1.24CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmcs: 0.57 · 95% CI 0.38 to 0.85CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmcs: 0.84 · 95% CI 0.56 to 1.27CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmcs: 0.64 · 95% CI 0.44 to 0.95CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmcs: 0.27 · 95% CI 0.18 to 0.40CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmcs: 1.14 · 95% CI 0.76 to 1.72CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmcs: 0.36 · 95% CI 0.25 to 0.51CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmcs: 0.79 · 95% CI 0.55 to 1.14CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmcs: 0.89 · 95% CI 0.61 to 1.28CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Ratio of gmcs: 0.86 · 95% CI 0.60 to 1.23CIs for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV/23vPS/13vPnC, PCV/PCV/13vPnC).
Other pre-specifiedPercentage of Participants Reporting Prespecified Local Reactions Within 4 Days of Vaccination

Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may have been represented in more than 1 category.

Time frame:
Day 1 through Day 4
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Prespecified Local Reactions Within 4 Days of Vaccination
Percentage of participantsPCV/23vPS/13vPnCPCV/PCV/13vPnC
Tenderness: Any88.076.9
Tenderness: Significant12.020.5
Redness: Any50.066.7
Redness: Mild10.015.8
Redness: Moderate40.052.6
Redness: Severe10.021.1
Swelling: Any44.059.0
Swelling: Mild16.326.3
Swelling: Moderate28.644.7
Swelling: Severe2.07.9
Statistical analysis
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = 0.253
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = 0.380
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = 0.135
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = 0.520
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = 0.283
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = 0.225
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = 0.202
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = 0.294
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = 0.175
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = 0.314
Other pre-specifiedPercentage of Participants Reporting Prespecified Systemic Reactions Within 4 Days of Vaccination

Pre-specified systemic events (any fever 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using a diary card. Participants may have been represented in more than 1 category.

Time frame:
Day 1 through Day 4
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Prespecified Systemic Reactions Within 4 Days of Vaccination
Percentage of participantsPCV/23vPS/13vPnCPCV/PCV/13vPnC
Fever ≥ 38 degrees C but ≤ 39 degrees C2.02.8
Decreased appetite12.210.3
Irritability18.411.4
Increased sleep4.012.8
Decreased sleep—5.1
Rash6.02.6
Statistical analysis
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = > .99
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = > .99
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = 0.543
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = 0.233
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = 0.198
  • PCV/23vPS/13vPnC vs PCV/PCV/13vPnC · Fisher Exact · p = 0.628

Adverse events

Collected over Baseline through 1 Month after last study vaccination (28 Days). Local reactions and systemic events assessed within 4 days of dose (Day 1 through Day 4). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PCV/23vPS/13vPnC—0/50 (0%)44/50 (88%)
PCV/PCV/13vPnC—0/39 (0%)30/39 (76.9%)
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPCV/23vPS/13vPnCPCV/PCV/13vPnC
Tenderness (Any)Skin and subcutaneous tissue disorders44/5030/39
Redness (Any)Skin and subcutaneous tissue disorders25/5026/39
Swelling (Any)Skin and subcutaneous tissue disorders22/5023/39
Redness (Moderate)Skin and subcutaneous tissue disorders20/5020/38
Swelling (Moderate)Skin and subcutaneous tissue disorders14/4917/38
Swelling (Mild)Skin and subcutaneous tissue disorders8/4910/38
Redness (Severe)Skin and subcutaneous tissue disorders5/508/38
Tenderness (Significant)Skin and subcutaneous tissue disorders6/508/39
IrritabilityGeneral disorders9/494/35
Redness (Mild)Skin and subcutaneous tissue disorders5/506/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)PCV/23vPS/13vPnCPCV/PCV/13vPnCTotal
Mean7.6 ± 0.27.6 ± 0.27.6 ± 0.2
Sex: Female, Male
Sex: Female, Male(Participants)PCV/23vPS/13vPnCPCV/PCV/13vPnCTotal
Female252045
Male251944
08

Study locations

2 sites
  • Landspitali University Hospital
    Hringbraut, Reykjavik 101, Iceland
  • Midstod Heilsuverndar barna
    Reykjavik, 109, Iceland
09

References and documents

Publications

  • Sigurdardottir ST, Center KJ, Davidsdottir K, Arason VA, Hjalmarsson B, Elisdottir R, Ingolfsdottir G, Northington R, Scott DA, Jonsdottir I. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children. Vaccine. 2014 Jan 9;32(3):417-24. doi: 10.1016/j.vaccine.2013.11.029. Epub 2013 Dec 2. PubMed 24300594 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2009 to primary completion in Dec 2009, 7 months.

Results were first posted in Jan 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2009
First posted
Mar 2, 2009
StartActual
May 5, 2009
Primary completionActual
Dec 16, 2009
CompletionActual
Dec 16, 2009
Results first posted
Jan 5, 2011
Last update
Nov 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00853749
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Mar 2, 2009
Start date
May 5, 2009
Primary completion
Dec 16, 2009
Completion
Dec 16, 2009
Results posted
Jan 5, 2011
Last update
Nov 11, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion